apo-quetiapine xr quetiapine (as fumarate) 200mg modified release tablets blister pack
medis pharma pty ltd - quetiapine fumarate -
apo-quetiapine xr quetiapine (as fumarate) 300mg modified release tablets blister pack
medis pharma pty ltd - quetiapine fumarate -
apo-quetiapine xr quetiapine (as fumarate) 400mg modified release tablets blister pack
medis pharma pty ltd - quetiapine fumarate -
terry white chemists duloxetine duloxetine (as hydrochloride) 60 mg enteric capsule blister pack
apotex pty ltd - duloxetine hydrochloride -
terry white chemists duloxetine duloxetine (as hydrochloride) 30 mg enteric capsule blister pack
apotex pty ltd - duloxetine hydrochloride -
chemmart duloxetine duloxetine (as hydrochloride) 60 mg enteric capsule blister pack
apotex pty ltd - duloxetine hydrochloride -
chemmart duloxetine duloxetine (as hydrochloride) 30 mg enteric capsule blister pack
apotex pty ltd - duloxetine hydrochloride -
sequase xr quetiapine (as fumarate) 400 mg modified release tablet blister pack
luye pharma australia pty ltd - quetiapine fumarate, quantity: 460.5 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).
sequase xr quetiapine (as fumarate) 300 mg modified release tablet blister pack
luye pharma australia pty ltd - quetiapine fumarate, quantity: 345.38 mg - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).
sequase xr quetiapine (as fumarate) 200 mg modified release tablet blister pack
luye pharma australia pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).